KIF11 and cancer: Because of secondary effects in normal cells and also because of resistance of cancer cells to such treatments, new targets have been explored, leading to the development of inhibitors of mitotic kinases such as Plk1 or Aurora, or of motor proteins such as Eg5 [24].